Sigrun Erkens‐Schulze

Author

Erasmus MC ORCID

Also Known As

S Erkens-Schulze, S. Erkens-Schulze, S. Erkens‐Schulze, Sigrun Erkens-Schulze, Sigrun Erkens‐Schulze

Publications

800

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Erasmus MC Cancer Institute Erasmus University Rotterdam Meertens Institute

About

Sigrun Erkens‐Schulze is an author at Erasmus MC specializing in medicine, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	143
2	Cell Biology	3	3	125
3	Engineering	2	2	38
4	Health Sciences	2	2	105
5	Biostatistics	1	1	20

Sigrun Erkens‐Schulze

Publications

690

Citations

H-Index

Page 1

	Year	Citations
Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models Rute B. Marques, Natasja F. Dits, Sigrun Erkens‐Schulze, PLoS ONE	2010	118
Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices Emma Jane Davies, Meng Dong, Matthias Gutekunst, Scientific Reports	2015	115
Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells Lisanne Mout, Lisanne F. van Dessel, Jaco Kraan, European Journal of Cancer UrologyTumor HeterogeneityMedicineTumour CellsCell Proliferation	2021	89
Androgen receptor modifications in prostate cancer cells upon long‐termandrogen ablation and antiandrogen treatment Rute B. Marques, Sigrun Erkens‐Schulze, Corrina M. de Ridder, International Journal of Cancer	2005	79
Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines Rute B. Marques, Natasja F. Dits, Sigrun Erkens‐Schulze, PLoS ONE	2011	53
Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis Jinpei Kumagai, Johannes Hofland, Sigrun Erkens‐Schulze, The Prostate	2013	45
Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response Wenhao Zhang, Wytske M. van Weerden, Corrina M.A. de Ridder, The Prostate	2018	38
CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance Anette Langebäck, Henriette Laursen, Lisanne Mout, Scientific Reports	2019	30
Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer Lisanne Mout, J.M. Moll, Mingqing Chen, British Journal of Cancer	2020	23
Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing Annelies Van Hemelryk, Lisanne Mout, Sigrun Erkens‐Schulze, Biomolecules EngineeringTreatment EffectComputational MedicineOncologyGenitourinary Cancer	2021	20

Page 1